Document is current
Any future updates will be listed below
-
Authors
Krivinko, J. M.
Fan, P.
Sui, Z.
Happe, C.
Hensler, C.
Gilardi, J. https://orcid.org/0009-0005-7711-609X
Ikonomovic, M. D.
McKinney, B. C. https://orcid.org/0000-0002-0663-7569
Newman, J.
Ding, Y. https://orcid.org/0000-0003-1352-1000
Wang, L.
Sweet, R. A. https://orcid.org/0000-0001-9154-9709
MacDonald, M. L.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (MH116046, AG027224, MH125235, MH118497, P01AG14449)
- License Information
-
More Information
Article History
Received: 22 March 2023
Revised: 14 October 2024
Accepted: 28 October 2024
First Online: 13 November 2024
Competing interests
: The University of Pittsburgh holds a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund (JMK). This work was supported in part by NIH grants: AG027224 and MH116046 (RAS), MH125235 and MH118497 (MLM), and P01AG14449 (MDI). RAS, JMK, PF, BCM, LW, and MLM are listed inventors on pending patent 63404994 filed by the University of Pittsburgh Innovation Institute. The methods of treating, preventing, or reducing dendritic spine density loss in a subject by administering one or a combination of the ten drugs listed in Fig. , or a pharmaceutically acceptable salt, prodrug, or derivative thereof, are protected by the patent.
: All methods were conducted in accordance with the University of Pittsburgh’s Committee for Oversight in Research Involving Decedents (ID 474) and the International Review Board for Biomedical Research (ID 19080015). Consent was obtained for all subjects from next of kin.
